Literature DB >> 10685800

Accurately describing changes in disease activity in Systemic Lupus Erythematosus.

D D Gladman1, M B Urowitz, A Kagal, D Hallett.   

Abstract

OBJECTIVE: To determine whether Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) scores correlate with the clinician's impression of level of disease activity.
METHODS: In total, 230 patients with SLE followed at the University of Toronto Lupus Clinic who had 5 visits 3 months apart in 1992-93 were studied. At each visit a standard protocol was completed. A clinician who did not know the patients or their SLEDAI scores evaluated each patient record and assigned a clinical activity level. "Flare" was defined by new or increased therapy for active disease, an expression of concern, or use of the term "flare" in the physician's notes. The SLEDAI score was calculated from the database.
RESULTS: SLEDAI scores described a range of clinical activity as recognized by the clinician. Median SLEDAI scores ranged from 2 (inactive disease) to 8 (persistently active or flare). When the clinician assessed the patient to be improved, the median SLEDAI score decreased by 2. When the clinician assessed that the patient was experiencing a flare, the SLEDAI score increased by a median of 4.
CONCLUSION: Based on our data we propose the following outcomes for patients with SLE: flare, an increase in SLEDAI > 3; improvement is a reduction in SLEDAI of > 3; persistently active disease is change in SLEDAI +/- 3; and remission a SLEDAI of 0. These outcomes will allow a more complete description of a patient's response to therapeutic intervention in a responder index.

Entities:  

Mesh:

Year:  2000        PMID: 10685800

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  35 in total

1.  Markers of childhood lupus nephritis indicating disease activity.

Authors:  Monika Edelbauer; Sudhir Kshirsagar; Magdalena Riedl; Dieter Haffner; Heiko Billing; Burkhard Tönshoff; Sophia Ross; Jörg Dötsch; Oliver Amon; Henry Fehrenbach; Christian Steuber; Antje Beissert; Josef Hager; Gottfried Wechselberger; Lutz T Weber; Lothar Bernd Zimmerhackl
Journal:  Pediatr Nephrol       Date:  2010-12-22       Impact factor: 3.714

2.  Hippocampal atrophy in systemic lupus erythematosus.

Authors:  S Appenzeller; A D Carnevalle; L M Li; L T L Costallat; F Cendes
Journal:  Ann Rheum Dis       Date:  2006-01-26       Impact factor: 19.103

Review 3.  Top 10 things to know about lupus activity measures.

Authors:  Aikaterini Thanou; Joan T Merrill
Journal:  Curr Rheumatol Rep       Date:  2013-06       Impact factor: 4.592

Review 4.  A critical review of clinical trials in systemic lupus erythematosus.

Authors:  M A Mahieu; V Strand; L S Simon; P E Lipsky; R Ramsey-Goldman
Journal:  Lupus       Date:  2016-09       Impact factor: 2.911

5.  Thyroid dysfunction in patients with systemic lupus erythematosus (SLE): relation to disease activity.

Authors:  Reuven Mader; Samer Mishail; Muhammed Adawi; Idit Lavi; Rafael Luboshitzky
Journal:  Clin Rheumatol       Date:  2007-03-20       Impact factor: 2.980

6.  Longitudinal expression of type I interferon responsive genes in systemic lupus erythematosus.

Authors:  M Petri; S Singh; H Tesfasyone; R Dedrick; K Fry; Pg Lal; G Williams; Jw Bauer; Pk Gregersen; Tw Behrens; Ec Baechler
Journal:  Lupus       Date:  2009-10       Impact factor: 2.911

7.  Neutrophil gelatinase-associated lipocalin is a predictor of the course of global and renal childhood-onset systemic lupus erythematosus disease activity.

Authors:  Claas H Hinze; Michiko Suzuki; Marisa Klein-Gitelman; Murray H Passo; Judyann Olson; Nora G Singer; Kathleen A Haines; Karen Onel; Kathleen O'Neil; Earl D Silverman; Lori Tucker; Jun Ying; Prasad Devarajan; Hermine I Brunner
Journal:  Arthritis Rheum       Date:  2009-09

8.  Novel evidence-based systemic lupus erythematosus responder index.

Authors:  Richard A Furie; Michelle A Petri; Daniel J Wallace; Ellen M Ginzler; Joan T Merrill; William Stohl; W Winn Chatham; Vibeke Strand; Arthur Weinstein; Marc R Chevrier; Z John Zhong; William W Freimuth
Journal:  Arthritis Rheum       Date:  2009-09-15

9.  Differential impact of systemic lupus erythematosus and rheumatoid arthritis on health-related quality of life.

Authors:  Benjamin Chaigne; Axel Finckh; Deshire Alpizar-Rodriguez; Delphine Courvoisier; Camillo Ribi; Carlo Chizzolini
Journal:  Qual Life Res       Date:  2017-03-11       Impact factor: 4.147

10.  Safety and Tolerability of Omalizumab: A Randomized Clinical Trial of Humanized Anti-IgE Monoclonal Antibody in Systemic Lupus Erythematosus.

Authors:  Sarfaraz Hasni; Sarthak Gupta; Michael Davis; Elaine Poncio; Yenealem Temesgen-Oyelakin; Elizabeth Joyal; Alice Fike; Zerai Manna; Sungyoung Auh; Yinghui Shi; Diana Chan; Philip Carlucci; Ann Biehl; Barbara Dema; Nicolas Charles; James E Balow; Meryl Waldman; Richard M Siegel; Mariana J Kaplan; Juan Rivera
Journal:  Arthritis Rheumatol       Date:  2019-05-08       Impact factor: 10.995

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.